Efifcacy and Safety of Albumin-bound Paclitaxel in Treating Recurrent Advanced Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2013.10.04
- VernacularTitle:苹果酸舒尼替尼治疗多次复发的晚期非小细胞肺癌疗效与安全性分析
- Author:
XING PUYUAN
1
;
LI JUNLING
;
SHI YUANKAI
Author Information
1. 100021北京，北京协和医学院，中国医学科学院肿瘤医院内科，抗肿瘤分子靶向药物临床研究北京市重点实验室
- Keywords:
Lung neoplsms;
Sunitinib;
Recurrence;
Tyrosine kinase inhibitors
- From:
Chinese Journal of Lung Cancer
2013;(10):519-523
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Advanced non-small cell lung cancer (NSCLC) is a common malignancy that is incurable. No standard treatment exists for recurrent patients. hTis article analyzed the effcacy and safety of sunitinib (37.5 mg qd) on a continuous daily dosing (CDD) schedule in treating recurrent advanced NSCLC. Methods We retrospec-tively analyzed the short-term effcacy and toxicity of sunitinib CDD in treating 17 patients who had previously undergone multiple cycles of therapy for advanced NSCLC in our hospital from January 2011 to December 2012. Treatment-related survival was also analyzed. Results Among the 17 patients, the best overall response was partial response in 1 patient (5.9%), stable disease in 7 patients (41.2%), and progressive disease in 9 patients (52.9%). hTe overall response rate was 5.9%, and the disease control rate was 47.1%. hTe median progression-free survival was 4.4 months (95%CI:4.05-7.46). hTe main grade 3/4 toxicity was hand-foot skin reaction. Conclusion Sunitinib (37.5 mg QD) CDD enabled good objective response in advanced NSCLC patients who had previously received multiple cycles of treatment and was well tolerated.
